Juvenile Arthritis

November 11, 2021

Hermine Brunner, MD, MSc, MBA, discusses secukinumab treatment in patients with enthesitis-related arthritis and juvenile psoriatic arthritis.

October 13, 2021

“Considering medical appointments, laboratory tests, medications, and indirect costs, juvenile idiopathic arthritis generates elevated costs, which results in a high economic impact for the family,” investigators stated.

October 05, 2021

Few data exist for the use of golimumab in patients whose uveitis does not respond to adalimumab, a first-line biologic choice in refractory juvenile idiopathic arthritis-associated uveitis.

September 30, 2021

While telemedicine is a valuable tool to provide access to care for families seeking care within a small subspecialty with a limited supply of providers, there was a significantly lower amount of new pediatric patient visits in the beginning of the COVID-19 pandemic.

September 22, 2021

As genetics only play a small role in the risk of developing juvenile idiopathic arthritis, environmental factors, such as infections and antibiotic usage, are believed to be the main cause of the disease.

September 09, 2021

Disease activity, safety, and the occurrence of adverse events were similar in patients with juvenile idiopathic arthritis receiving either etanercept or the biosimilars Benepali and Erelzi.

August 27, 2021

“Juvenile idiopathic arthritis constitutes a significant cause of disability and quality of life impairment in pediatric and adult patients,” investigators stated. “Recent advances in JIA treatment addressing more specific targets have led to better short and long-term disease outcomes."

July 28, 2021

Many children with juvenile idiopathic arthritis stop vaccinating when diagnosis is established, despite them being at a greater risk of infections than healthy children due to their aberrant immunity and the use of immunosuppressive drugs.

July 19, 2021

Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.

June 21, 2021

Rheumatology Network interviewed Hermine Brunner, MD, MSc, MBA, lead investigator of the JUNIPERA study, which reported on the safety and efficacy of secukinumab for patients with juvenile idiopathic arthritis (JIA), presented at the EULAR 2021 Virtual Congress. Secukinumab was the first approved biologic for specific JIA categories in the US and marked improvement of skin involvement with juvenile spondyloarthritis (jPSA) and increased quality of life for children with chronic arthritis plus psoriasis.